Skip to content

Comparison of General Anesthesia Hemodynamics Between R and P in Patients Undergoing Laparoscopic Hepatectomy

Comparison of General Anesthesia Hemodynamics Between Remimazolam and Propofol in Patients Undergoing Laparoscopic Hepatectomy: a Randomized, Controlled Trial.

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06714669
Enrollment
88
Registered
2024-12-03
Start date
2024-06-20
Completion date
2024-10-30
Last updated
2024-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypotension During Surgery

Keywords

hypotension, hemodynamics, general anesthesia, remimazolam, propofol

Brief summary

This study is a randomized controlled trial designed to investigate the effects of two anesthetics, remimazolam and propofol, on intraoperative hemodynamics in patients undergoing laparoscopic liver resection. The experimental group receives remimazolam, while the control group receives propofol. The primary objective is to compare the hemodynamic responses of patients in both groups during the surgical procedure, aiming to provide insights into the potential differences in cardiovascular stability and anesthetic management associated with these two drugs

Interventions

DRUGpropofol

Control Group (Propofol Anesthesia Arm): Patients in this arm will receive Propofol as the primary anesthetic agent for general anesthesia. Propofol is a well-established anesthetic drug commonly used in clinical practice for its rapid onset and short duration of action. Similar to the experimental group, the dosing regimen and administration protocol for Propofol will be tailored to the individual patient's needs and the surgical procedure. Hemodynamic stability and other vital signs will also be closely monitored in this group to assess the safety and effectiveness of Propofol in comparison to Remimazolam.

DRUGRemimazolam

Experimental Group (Remimazolam Anesthesia Arm): Patients in this arm will receive Remimazolam as the primary anesthetic agent for inducing and maintaining general anesthesia. Remimazolam belongs to a new class of benzodiazepines and acts by enhancing the activity of GABAA receptors, leading to sedation and anesthesia. The specific dosing regimen and administration protocol for Remimazolam will be determined based on the patient's characteristics and the surgical procedure being performed. Close monitoring of the patient's vital signs, particularly hemodynamic parameters, will be conducted throughout the anesthesia period to ensure safety and efficacy.

Sponsors

Sun Yat-sen University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Caregiver)

Masking description

In order to ensure the management of perioperative anesthesia and the safety of patients, this study is a single-blind study, that is, anesthesiologists know what kind of anesthesia they have received, and carry out anesthesia plans for patients according to groups (group P / R). Participants and postoperative evaluators will not know the grouping of patients.

Intervention model description

participants in the experimental group used remimazolam as intravenous anesthetics while participants in the control group used propofol.

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Scheduled for LMH; * Age 18-80 years, BMI 18-28 kg/m2; * American Association of Anesthesiologists(ASA)I-III; * Child-Pugh grade A or B; * No serious heart, brain and other important organ lesions; * Informed and consent, and signed informed consent.

Exclusion criteria

* ASA IV-V or Child-Pugh C; * Left ventricular ejection fraction (EF) \<30%; * Implanted with temporary or permanent pacemakers; * Organic heart disease; * Uncontrolled hypertension, diabetes and other chronic diseases; * Prolonged use of sedative and analgesic drugs (such as opioid analgesics, benzodiazepines, antianxiety, antidepressants, antipsychotics, etc.); * Alcohol addiction; * Allergic to benzodiazepines or propofol, or to any ingredient in the studied drug; * Known history of allergy to other anesthetics; difficulty in airway and intubation during induction.

Design outcomes

Primary

MeasureTime frameDescription
Blood pressureFrom enrollment to the end of treatment at 4 weeksThe primary focus is to evaluate and compare the impact of Remimazolam and Propofol on hemodynamic parameters such as blood pressure (both systolic and diastolic). The objective is to assess whether Remimazolam causes less hemodynamic fluctuation compared to Propofol during the induction and maintenance of general anesthesia.
Heart rateFrom enrollment to the end of treatment at 4 weeksThe primary focus is to evaluate and compare the impact of Remimazolam and Propofol on hemodynamic parameters such as heart rate. The objective is to assess whether Remimazolam causes less hemodynamic fluctuation compared to Propofol during the induction and maintenance of general anesthesia.
Mean arterial pressureFrom enrollment to the end of treatment at 4 weeksThe primary focus is to evaluate and compare the impact of Remimazolam and Propofol on hemodynamic parameters such as mean arterial pressure. The objective is to assess whether Remimazolam causes less hemodynamic fluctuation compared to Propofol during the induction and maintenance of general anesthesia.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026